Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994052 | 1.00 | TRPV1 (0.48) | TRPV1CCKARCCKBRMEN1KMT2A | |
| SCHEMBL18272413 | 0.93 | TRPV1 (0.42) | TRPV1USP30 | |
| SCHEMBL16999367 | 0.85 | HPGDS (0.46) | TRPV1CCKARCCKBRHPGDSHTT | |
| SCHEMBL16993988 | 0.85 | HPGDS (0.46) | TRPV1CCKARCCKBRHPGDSHTT | |
| SCHEMBL16994022 | 0.84 | TRPV1 (0.53) | TRPV1MEN1KMT2AMAPK1HTT | |
| SCHEMBL16994042 | 0.84 | TRPV1 (0.53) | TRPV1MEN1KMT2AKCNA5MAPK1 | |
| SCHEMBL16994005 | 0.84 | TRPV1 (0.55) | TRPV1MEN1KMT2AMAPK1HTT | |
| SCHEMBL16999333 | 0.84 | TRPV1 (0.53) | TRPV1MEN1KMT2AMAPK1HTT | |
| SCHEMBL19976992 | 0.83 | TRPV1 (0.48) | TRPV1MEN1KMT2AKCNA5MAPK1 | |
| SCHEMBL30172750 | 0.83 | MEN1 (0.58) | TRPV1MEN1KMT2AMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023378-A1 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH Nα-AROYL- N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3102193-B1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | UNIV RUTGERS (US) | 2023-01-11 | — | — | EP | disclosed |
| US-9919998-B2 | Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160347708-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2016-12-01 | — | — | US | disclosed |
| WO-2015120320-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347708-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | TYR, NAT1, AANAT | TRPV1 3092/4885CCKAR 3247/4885CCKBR 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.